Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b)

Am J Clin Pathol. 1997 Oct;108(4):378-82. doi: 10.1093/ajcp/108.4.378.


A scoring system, based on the immunophenotypic analysis of a panel of five membrane markers (CD5, CD22, CD23, FMC7, SmIg) was shown to be useful in the distinction between chronic lymphocytic leukemia (CLL) and other B-cell lymphoproliferative diseases (non-CLL). We investigated whether the monoclonal antibody SN8 (CD79b) could improve our previous scoring system. Peripheral blood samples of 298 patients with CLL and 166 patients with non-CLL were analyzed by flow cytometry. Using the five standard markers, the accuracy of the scoring system was 91.8%, using a cutoff of 4 points or higher, to distinguish CLL from non-CLL. This was increased to 96.6% if SN8 was added and a cutoff of 4 points or higher was also used. A similar accuracy, 96.8%, was observed if CD22 was excluded and a cutoff of 3 points or higher was used. Thus, the replacement of CD22 by SN8 in the original scoring system significantly increases its potential to discriminate between CLL and other B-cell lymphoproliferative diseases.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal*
  • Antigens, CD / analysis*
  • Biomarkers, Tumor / analysis
  • CD79 Antigens
  • Diagnosis, Differential
  • Flow Cytometry
  • Humans
  • Immunophenotyping / methods*
  • Leukemia, B-Cell / immunology
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis*
  • Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
  • Lymphoma, B-Cell / immunology


  • Antibodies, Monoclonal
  • Antigens, CD
  • Biomarkers, Tumor
  • CD79 Antigens
  • CD79B protein, human